Related references
Note: Only part of the references are listed.Role of Casein Kinase 1A1 in the Biology and Targeted Therapy of del(5q) MDS
Rebekka K. Schneider et al.
CANCER CELL (2014)
Myelodysplastic Syndromes Are Propagated by Rare and Distinct Human Cancer Stem Cells In Vivo
Petter S. Woll et al.
CANCER CELL (2014)
Csnk1a1 inhibition has p53-dependent therapeutic efficacy in acute myeloid leukemia
Marcus Jaeras et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2014)
Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
A. F. List et al.
LEUKEMIA (2014)
SETBP1 mutation analysis in 944 patients with MDS and AML
F. Thol et al.
LEUKEMIA (2013)
Recurrent mutations in the U2AF1 splicing factor in myelodysplastic syndromes
Timothy A. Graubert et al.
NATURE GENETICS (2012)
Prognostic Significance of ASXL1 Mutations in Patients With Myelodysplastic Syndromes
Felicitas Thol et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Martin Jaedersten et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
CKIα ablation highlights a critical role for p53 in invasiveness control
Ela Elyada et al.
NATURE (2011)
Suppression of Casein Kinase 1α in Melanoma Cells Induces a Switch in β-Catenin Signaling to Promote Metastasis
Tobias Sinnberg et al.
CANCER RESEARCH (2010)
Identification of miR-145 and miR-146a as mediators of the 5q-syndrome phenotype
Daniel T. Starczynowski et al.
NATURE MEDICINE (2010)
Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays
Li Wang et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Identification of RPS14 as a 5q- syndrome gene by RNA interference screen
Benjamin L. Ebert et al.
NATURE (2008)